Sonoma Pharma Details Executive Pay, Governance Ahead of Shareholder Vote
Ticker: SNOA · Form: DEF 14A · Filed: Jul 11, 2025 · CIK: 1367083
Sentiment: neutral
Topics: Executive Compensation, Corporate Governance, Proxy Statement, Shareholder Vote, Medical Devices, SEC Filing, SNOA
Related Tickers: SNOA
TL;DR
**SNOA's executive compensation package is under the microscope; watch for shareholder approval to gauge investor confidence.**
AI Summary
Sonoma Pharmaceuticals, Inc. (SNOA) filed its DEF 14A, indicating a focus on executive compensation and corporate governance for the fiscal year ending March 31, 2025. The filing details the compensation structure for its Named Executive Officers (NEOs), including stock awards and option awards. For the period April 1, 2024, to March 31, 2025, the company reported specific amounts for stock and option awards, as well as their fair value at fiscal year-end for outstanding and unvested awards. The document also outlines changes in fair value of awards from prior fiscal years and the fair value of awards that vested during the fiscal year. While specific revenue and net income figures are not directly provided in this DEF 14A, the emphasis on executive compensation suggests ongoing operational activities and a need to align executive incentives with shareholder value. Risks related to compensation practices and shareholder approval of proposals are implicit in a proxy statement. The strategic outlook involves maintaining competitive executive compensation to attract and retain talent, crucial for a company in the surgical and medical instruments sector.
Why It Matters
This DEF 14A filing is critical for investors as it outlines Sonoma Pharmaceuticals' executive compensation practices and corporate governance proposals, which directly impact shareholder value and company performance. Understanding how executives are incentivized provides insight into management's alignment with long-term strategic goals. For employees, these compensation structures can influence morale and retention within the competitive surgical and medical instruments industry. Customers and the broader market will observe the company's commitment to sound governance, which can affect its reputation and competitive standing against rivals like Johnson & Johnson or Medtronic.
Risk Assessment
Risk Level: medium — The risk level is medium because while a DEF 14A primarily focuses on governance, the details of executive compensation, particularly stock and option awards for the fiscal year ending March 31, 2025, can signal potential misalignment with shareholder interests if not structured appropriately. Shareholder dissent on compensation proposals could lead to governance challenges and impact investor sentiment, as seen in the detailed reporting of fair value changes and forfeitures.
Analyst Insight
Investors should carefully review the executive compensation proposals and vote accordingly, paying close attention to the 'Amount Reported Under The Stock Awards And Option Awards Columns' for the fiscal year ending March 31, 2025. Evaluate whether the proposed compensation aligns with company performance and long-term shareholder value creation.
Financial Highlights
- debt To Equity
- 0.0
- revenue
- $0
- operating Margin
- 0%
- total Assets
- $0
- total Debt
- $0
- net Income
- $0
- eps
- $0
- gross Margin
- 0%
- cash Position
- $0
- revenue Growth
- +0%
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Not Specified | Not Specified | $0 |
Key Numbers
- 2025-03-31 — Fiscal Year End (Period for which executive compensation data is reported)
- 001-33216 — SEC File Number (Unique identifier for Sonoma Pharmaceuticals' SEC filings)
- 61 — Public Document Count (Number of documents in the filing)
- 2025-07-11 — Filed As Of Date (Date the DEF 14A was officially filed with the SEC)
- 3841 — SIC Code (Standard Industrial Classification for Surgical & Medical Instruments & Apparatus)
Key Players & Entities
- Sonoma Pharmaceuticals, Inc. (company) — filer of DEF 14A
- SNOA (company) — ticker symbol
- March 31, 2025 (date) — fiscal year end for compensation reporting
- Boulder, CO (location) — business address of Sonoma Pharmaceuticals
- 0001367083 (regulator) — Central Index Key (CIK) for Sonoma Pharmaceuticals
- Oculus Innovative Sciences, Inc. (company) — former name of Sonoma Pharmaceuticals
- 2006-06-22 (date) — date of name change from Oculus Innovative Sciences, Inc.
- DEF 14A (regulator) — SEC filing type
- SEC (regulator) — Securities and Exchange Commission
- Bloomberg (company) — publisher of analysis
FAQ
What is the purpose of Sonoma Pharmaceuticals' DEF 14A filing?
Sonoma Pharmaceuticals' DEF 14A filing serves as a definitive proxy statement, providing shareholders with crucial information regarding matters to be voted upon at the upcoming annual meeting, including executive compensation for the fiscal year ending March 31, 2025, and corporate governance proposals.
How does Sonoma Pharmaceuticals compensate its executives?
Sonoma Pharmaceuticals compensates its executives through a combination of stock awards and option awards, as detailed in the 'Amount Reported Under The Stock Awards And Option Awards Columns' for the fiscal year ending March 31, 2025. The filing also tracks the fair value of outstanding, unvested, and vested awards.
What financial periods are covered in the Sonoma Pharmaceuticals DEF 14A for compensation data?
The Sonoma Pharmaceuticals DEF 14A covers executive compensation data for the fiscal years ending March 31, 2025, March 31, 2024, and March 31, 2023, allowing for a three-year comparison of awards and their fair values.
What is the significance of the 'Fair Value As Of Fiscal Year End' data in Sonoma Pharmaceuticals' filing?
The 'Fair Value As Of Fiscal Year End' data for Sonoma Pharmaceuticals' awards granted during the fiscal year that are outstanding and unvested as of March 31, 2025, indicates the potential future value of executive compensation, which is important for assessing long-term incentive alignment.
When was Sonoma Pharmaceuticals' DEF 14A filed?
Sonoma Pharmaceuticals' DEF 14A was filed on July 11, 2025, with the Securities and Exchange Commission, making it publicly available for investor review.
What industry does Sonoma Pharmaceuticals operate in?
Sonoma Pharmaceuticals, Inc. operates in the Surgical & Medical Instruments & Apparatus industry, as indicated by its Standard Industrial Classification (SIC) code 3841.
What was Sonoma Pharmaceuticals' former company name?
Sonoma Pharmaceuticals, Inc. was formerly known as Oculus Innovative Sciences, Inc., with the name change occurring on June 22, 2006.
How can shareholders access the full Sonoma Pharmaceuticals DEF 14A document?
Shareholders can access the full Sonoma Pharmaceuticals DEF 14A document via the SEC's EDGAR database using the accession number 0001683168-25-005049, filed on July 11, 2025.
What are the potential risks associated with executive compensation at Sonoma Pharmaceuticals?
Potential risks at Sonoma Pharmaceuticals include shareholder dissatisfaction if executive compensation, particularly stock and option awards for the fiscal year ending March 31, 2025, is perceived as excessive or not adequately tied to performance, which could lead to negative votes on compensation proposals.
What is the significance of the 'Change In Fair Value' data for Sonoma Pharmaceuticals' awards?
The 'Change In Fair Value' data for Sonoma Pharmaceuticals' awards, both outstanding and vested, for the fiscal year ending March 31, 2025, highlights the fluctuations in the value of executive incentives, providing insight into the performance of equity-based compensation over time.
Risk Factors
- Compliance with FDA Regulations [high — regulatory]: Sonoma Pharmaceuticals operates in the medical device sector, which is subject to stringent regulations by the U.S. Food and Drug Administration (FDA) and similar international bodies. Failure to comply with these regulations regarding product development, manufacturing, and marketing can lead to product recalls, fines, and reputational damage.
- Competition in Surgical and Medical Instruments [medium — market]: The company faces intense competition from both large, established players and smaller, innovative companies in the surgical and medical instruments market. Maintaining market share and profitability requires continuous innovation, effective sales strategies, and competitive pricing.
- Supply Chain Disruptions [medium — operational]: Disruptions in the global supply chain, as experienced in recent years, can impact the availability of raw materials and components necessary for manufacturing medical devices. This could lead to production delays and increased costs.
- Dependence on Key Products [medium — financial]: The company's financial performance may be heavily reliant on the success and market adoption of a limited number of key products. Any adverse developments related to these products, such as clinical trial failures or market rejection, could significantly impact revenue.
- Intellectual Property Protection [medium — legal]: Protecting intellectual property is crucial in the pharmaceutical and medical device industry. Litigation or challenges to the company's patents or proprietary technology could result in significant legal costs and loss of competitive advantage.
Industry Context
Sonoma Pharmaceuticals operates within the highly competitive surgical and medical instruments sector. This industry is characterized by rapid technological advancements, a strong emphasis on research and development, and rigorous regulatory oversight. Companies in this space must continuously innovate to meet evolving healthcare needs and maintain a competitive edge against both established giants and agile startups.
Regulatory Implications
As a medical device company, Sonoma Pharmaceuticals is subject to extensive regulatory scrutiny from bodies like the FDA. Compliance with manufacturing standards, product approvals, and post-market surveillance is paramount. Any lapses in compliance can lead to significant penalties, product recalls, and damage to the company's reputation and financial standing.
What Investors Should Do
- Review executive compensation details
- Assess corporate governance practices
- Monitor industry trends and competitive landscape
Key Dates
- 2025-03-31: Fiscal Year End — Marks the end of the reporting period for which executive compensation and award data are detailed in the DEF 14A.
- 2025-07-11: DEF 14A Filing Date — The date the definitive proxy statement was officially filed with the SEC, making the information publicly available to shareholders.
- 2006-06-22: Company Name Change — Indicates the former name of the company was Oculus Innovative Sciences, Inc., prior to its rebranding to Sonoma Pharmaceuticals, Inc.
Glossary
- DEF 14A
- A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information about executive compensation, corporate governance, and matters to be voted on at the annual shareholder meeting. (This document is the primary source of information regarding executive pay and governance practices at Sonoma Pharmaceuticals.)
- Named Executive Officers (NEOs)
- The top executive officers of a company, typically including the CEO, CFO, and other principal executive officers, whose compensation is disclosed in proxy statements. (The DEF 14A focuses on the compensation awarded to these key individuals.)
- Stock Awards
- Grants of company stock or units of stock to employees, often as part of their compensation package, which may be subject to vesting conditions. (A significant component of executive compensation detailed in the filing, reflecting incentives tied to company performance.)
- Option Awards
- Grants that give employees the right to purchase company stock at a predetermined price (the exercise price) within a specified period. (Another key element of executive compensation, providing potential upside if the stock price increases.)
- Fair Value
- The estimated worth of an asset or liability, often determined using valuation models, as of a specific date. For stock and option awards, it reflects the market value at the time of grant or fiscal year-end. (Used to quantify the value of executive awards granted and outstanding.)
- Vesting
- The process by which an employee earns the right to receive or exercise an award, typically over a period of time or upon achievement of certain performance goals. (Crucial for understanding when executives can realize the value of their stock and option awards.)
- SIC Code 3841
- Standard Industrial Classification code for 'Surgical & Medical Instruments & Apparatus', indicating the company's primary business sector. (Classifies Sonoma Pharmaceuticals within the medical technology industry, highlighting its operational focus.)
Year-Over-Year Comparison
The provided DEF 14A for the fiscal year ending March 31, 2025, focuses on executive compensation and governance. Specific comparative financial metrics such as revenue growth, margin changes, or net income from the previous fiscal year (ending March 31, 2024) are not detailed within this excerpt. Therefore, a direct comparison of key financial performance indicators to the prior filing is not possible based on the information presented.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on July 11, 2025 regarding Sonoma Pharmaceuticals, Inc. (SNOA).